Kitada Y
Pharmaceutical Laboratory I, Yokohama Research Center, Mitsubishi Chemical Corporation, Japan.
Cardiovasc Drugs Ther. 1997 Nov;11(5):611-8. doi: 10.1023/a:1007709421375.
Intracellular accumulation of inorganic phosphate (Pi) and intracellular acidosis, which occur in ischemic and hypoxic hearts, reduce the force of contraction by decreasing the responsiveness of contractile system to Ca2+. In the present study we investigated the effects of MCI-154, a Ca2+ sensitizer that can enhance crossbridge interaction, on the decline in maximal Ca2+-activated force by Pi or acidic pH in skinned fiber bundles of guinea pig hearts. MCI-154 can concentration-dependently reverse the depression in maximal Ca2+-activated force (pCa 4.4) by 20 mM Pi, which was not recovered by a higher concentration of Ca2+ ion (pCa 4.0). The effects of MCI-154 were observed even at a concentration (0.01 M) at which the drug has no effect on the pCa 4.4-induced maximal force in the absence of 20 mM Pi when given alone. MCI-154 inhibited the rightward shift of the pCa-tension relationships, with a marked decrease of maximal force produced by 20 mM Pi or acidic pH (decrease in pH from 7.0 to 6.6). MCI-154 also improved the decline in maximal Ca2+-activated force by 20 mM Pi under acidic pH, but the acidosis did not further decrease the effect of 20 mM Pi. Milrinone, a cyclic AMP-dependent phosphodiesterase inhibitor, and pimobendan, another Ca2+ sensitizer, did not improve the Pi-induced contractile failure. These results indicate that the Ca2+ sensitizer MCI-154 could reverse the contractile failure induced by Pi and/or acidic pH in a skinned fiber preparation via modulation of the strong crossbridge reaction with myosin. MCI-154 may be a promising agent for myocardial contractile failure, in which Pi and H+ progressively increase.
无机磷酸盐(Pi)在细胞内的蓄积以及细胞内酸中毒发生于缺血和缺氧的心脏中,它们通过降低收缩系统对Ca2+的反应性来减弱收缩力。在本研究中,我们研究了MCI - 154(一种可增强横桥相互作用的Ca2+敏化剂)对豚鼠心脏肌纤维束中由Pi或酸性pH引起的最大Ca2+激活力下降的影响。MCI - 154可浓度依赖性地逆转20 mM Pi引起的最大Ca2+激活力(pCa 4.4)的降低,更高浓度的Ca2+离子(pCa 4.0)并不能使其恢复。即使在单独给予时该药物对不存在20 mM Pi时的pCa 4.4诱导的最大力无影响的浓度(0.01 M)下,仍可观察到MCI - 154的作用。MCI - 154抑制了pCa - 张力关系的右移,显著降低了由20 mM Pi或酸性pH(pH从7.0降至6.6)产生的最大力。MCI - 154还改善了酸性pH下20 mM Pi引起的最大Ca2+激活力的下降,但酸中毒并未进一步降低20 mM Pi的作用。米力农(一种环磷酸腺苷依赖性磷酸二酯酶抑制剂)和匹莫苯丹(另一种Ca2+敏化剂)并不能改善Pi诱导的收缩功能衰竭。这些结果表明,Ca2+敏化剂MCI - 154可通过调节与肌球蛋白的强横桥反应,逆转去皮纤维制剂中由Pi和/或酸性pH诱导的收缩功能衰竭。MCI - 154可能是治疗心肌收缩功能衰竭的一种有前景的药物,在心肌收缩功能衰竭中Pi和H+会逐渐增加。